NXPL · NextPlat Corp
The latest filing states the doubt was alleviated.
“These conditions raised substantial doubt about the Company's ability to continue as a going concern for the twelve months following the issuance of these Condensed Consolidated Financial Statements. Management has evaluated its plans to mitigate these conditions. These plans include expanding the Company's long-term care pharmacy operations, increasing 340B contract pharmacy revenue, developing additional institutional medication fulfillment contracts, and implementing identified operational efficiencies. For the six months ended June 30, 2026, operating loss decreased to approximately $1.2 million from $3.9 million, and cash used in operating activities decreased to approximately $1.5 million from $3.1 million. As of June 30, 2026, the Company had cash of approximately $11.9 million and $3.8 million of remaining availability under the ATM Program. Based on these results, management's projections of operating results and cash flows for the twelve months following issuance, and the Company's liquidity position, management has concluded that its plans, which are probable of being effectively implemented and probable of mitigating the relevant conditions, alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $48.89M | $54.32M | $66.08MG | $37.76M | $11.71M | $7.74M | $5.69M | $5.87M | $5.73M | $6M | $4.7M | $3.95M | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $6069 | — | -$120.58K | -$127.48K | -$658.16K | -$439.79K | |
| $35.63M | $43.42M | $49.07M | $26.45M | $9.22M | $5.88M | $4.46M | $4.65M | $4.69M | $4.85M | $3.62M | $2.97M | $1.74M | — | — | — | — | |
| $13.27M | $10.91M | $17.01M | $11.31M | $2.49M | $1.86M | $1.23M | $1.22M | $1.03M | $1.15M | $1.08M | $984.48K | $681.26K | — | — | — | — | |
| — | 20.08% | 25.74% | 29.96% | 21.26% | 24.03% | 21.54% | 20.84% | 18.07% | 19.16% | 22.88% | 24.92% | — | — | — | — | — | |
| $0 | — | — | — | — | $0 | $0 | — | $0 | $0 | $0 | $50K | $0 | — | — | — | — | |
| $800.92K | — | — | — | — | — | — | — | — | — | — | $644.87K | $401.11K | $573.79K | $98.55K | $341.23K | $333.61K | |
| $6.48M | $6.04M | $6.18M | $9.91M | $5.09M | $5.13M | $694.36K | $761.24K | $664.82K | $583.9K | $566.19K | $517.27K | — | — | — | — | — | |
| $102K | $102K | $1.71M | $1.34M | $25K | $25K | $25K | $25K | $25K | $25K | $25K | $25K | — | — | — | — | $381 | |
| — | $540K | $788K | $2.11M | $490K | $317.1K | $294.93K | $275.33K | $263.86K | $259.39K | $266.8K | $154K | $20.6K | — | — | — | — | |
| $19.58M | $19.91M | $40.03M | $34.54M | $9.69M | $8.48M | $3.26M | $2.33M | $2.16M | $2.71M | $2.71M | $2.98M | $667.44K | $573.79K | $4.67M | $1.94M | $4.29M | |
| -$6.32M | -$9M | -$23.03M | -$23.23M | -$7.2M | -$6.62M | -$2.03M | -$1.11M | -$1.13M | -$1.58M | -$1.63M | -$1.99M | $13.82K | -$573.79K | -$4.67M | -$1.94M | -$4.29M | |
| — | -16.57% | -34.84% | -61.52% | -61.51% | -85.56% | -35.75% | -18.93% | -19.73% | -26.27% | -34.7% | -50.41% | — | — | — | — | — | |
| — | -$8.46M | -$22.24M | -$21.12M | -$6.71M | -$6.31M | -$1.74M | -$836K | -$865.77K | -$1.32M | -$1.36M | -$1.84M | $34.42K | — | — | — | — | |
| — | $64K | $81K | $79K | $24K | — | — | — | — | — | — | — | — | $33.27K | $119.15K | — | — | |
| — | $358K | $731K | $620K | $21K | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$1.68M | -$1.46M | $570K | $937K | -$132K | -$1.49M | -$729.5K | $267.68K | $56.54K | $2.36M | $959.4K | $72.89K | $7325 | $1.2M | -$140.87K | -$6.78M | -$6.19M | |
| — | — | $0 | -$1.44M | -$1.74M | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$8M | -$10.46M | -$22.46M | -$12.38M | -$9.07M | -$8.11M | -$2.76M | -$1.38M | -$1.19M | -$3.92M | -$2.59M | -$2.06M | $6490 | $624.12K | -$4.81M | -$8.72M | -$10.48M | |
| $8000 | $0 | $71K | $28K | $87K | — | — | $747 | $8534 | $23.46K | — | — | — | — | — | — | — | |
| $2.46M | -$10.46M | -$14.03M | -$3.78M | -$9.16M | -$8.11M | -$2.76M | -$1.38M | -$1.19M | -$3.94M | -$2.59M | -$2.06M | $6490 | $624.12K | -$4.81M | -$8.72M | -$11.58M | |
| — | -19.26% | -21.22% | -10.01% | -78.23% | -104.75% | -48.57% | -23.51% | -20.86% | -65.6% | -55.12% | -52.25% | — | — | — | — | — | |
| -$14K | $0 | -$9.1M | -$8.63M | $0 | — | — | — | — | — | — | — | — | — | $4.8M | — | — | |
| -$9.24M | -$11.71M | -$13.43M | -$3.78M | -$9.16M | — | -$2.76M | -$1.18M | — | -$3.91M | -$2.61M | -$2.08M | $5641 | $624.12K | — | — | — | |
| -$7.97M | -$10.52M | -$22.53M | -$12.43M | -$9.2M | -$8.06M | -$2.8M | -$1.38M | -$1.2M | -$3.91M | — | — | — | — | — | — | — | |
| USD/shares | -$3.43 | -$4.40 | -$6.50 | -$2.20 | -$9.60 | -$19.80 | — | — | — | -$81.00 | -$114.20 | -$2.60 | $0.00 | $3.80 | — | — | — |
| USD/shares | — | -$4.40 | -$6.50 | -$2.20 | -$9.60 | — | — | — | — | -$81.00 | -$114.20 | -$2.60 | $0.00 | $3.60 | — | — | — |
| shares | — | 2.65M | 2.06M | 1.75M | 959.2K | 408.08K | 2123.5 | 10.62K | 6243.5 | 48.25K | 22.85K | 799.41K | 254K | 166.13K | 24.93M | 22.01M | — |
| shares | — | 2.65M | 2.06M | 1.75M | 959.2K | 408.08K | 2123.5 | 10.62K | 6243.5 | 48.25K | 22.85K | 799.41K | 9M | 171.46K | 24.93M | 22.01M | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2014–FY2025: $100K in buybacks, $133.27K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 79 similar-size Software - Application companies (of 202 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Healthcare Operations | $39,714,000 | $52,291,000 | $26,779,000 | $0 |
| Ecommerce | $14,608,000 | $13,791,000 | $10,977,000 | $11,710,000 |
| Ecommerce Revenue | $14,608,000 | $13,791,000 | $10,977,000 | $11,710,000 |
By Geography (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| Europe | $5,146,336 | $3,658,612 |
| North America | $1,776,288 | $1,532,273 |
| Asia Pacific | $695,770 | $420,048 |
| Africa | $84,377 | $43,948 |
| South America | $37,139 | $34,915 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Pharmacy Prescription and Other Revenue Net of PBM Fees | $35,704,000 | $41,907,000 | $21,412,000 | $0 |
| Ecommerce Revenue | $14,608,000 | $13,791,000 | $10,977,000 | $11,710,000 |
| Pharmacy 340B Contract | $4,010,000 | $10,384,000 | $5,367,000 | $0 |
| Ecommerce | — | $13,791,000 | $10,977,000 | $11,710,000 |
| Pharmacy Prescription Other Revenue and Ecommerce | — | $55,099,000 | $32,389,000 | $11,710,000 |
| Product | — | $55,540,000 | $32,389,000 | $11,710,000 |
| Service | — | $10,542,000 | $5,367,000 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Ecommerce | -$4,396,000 | -$6,510,000 | -$8,690,000 | -$7,203,000 |
| Healthcare Operations | -$4,604,000 | -$16,755,000 | -$14,658,000 | $0 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Healthcare Operations | -11.6% | -32% | -54.7% | — |
| Ecommerce | -30.1% | -47.2% | -79.2% | -61.5% |